百合地黄汤加味联合艾司西酞普兰治疗围绝经期2型糖尿病合并抑郁症的疗效及对血糖、抑郁症状的影响OA
Effect of modified Baihe Dihuang decoction combined with escitalopram in the treatment of perimenopausal type 2 diabetes mellitus with depressive disorder and its effect on blood glucose and depressive symptoms
目的 探讨百合地黄汤加味联合艾司西酞普兰治疗围绝经期2型糖尿病(T2DM)合并抑郁症(DD)的临床疗效及对血糖、抑郁症状的影响.方法 选取2022年8月至2024年3月该院收治的112例围绝经期T2DM合并DD患者作为研究对象,采用随机数字表法分为百合组和艾司组,每组56例.2组均进行常规治疗,艾司组采用艾司西酞普兰治疗,百合组采用百合地黄汤加味+艾司西酞普兰治疗.比较艾司组和百合组血糖指标[空腹血糖(FPG)、平均餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)]水平、抑郁症状评分和总分、血清性激素[卵泡刺激素(FSH)、雌二醇(E2)、黄体生成素(LH)]水平、临床疗效、不良反应发生情况.结果 治疗后,2组FPG、2 hPG、HbA1c、E2、FSH、LH水平均低于治疗前,E2 水平均高于治疗前,且治疗后百合组FPG、2 hPG、HbA1c、FSH、LH 水平均低于艾司组,E2 水平高于艾司组,差异均有统计学意义(P<0.05).治疗后,2组汉密尔顿抑郁量表中抑郁情绪、有罪感、自杀、入睡困难初段失眠、睡眠不深中段失眠、早醒末段失眠、工作和兴趣、阻滞、激越、精神性焦虑、躯体性焦虑、胃肠道症状、性症状、疑痛、体质量减轻、自知力评分及总分均低于治疗前,且百合组上述抑郁症状评分和总分均低于艾司组,差异均有统计学意义(P<0.05).百合组治疗总有效率为94.64%,高于艾司组的71.43%,差异有统计学意义(P<0.05).百合组(5.36%)和艾司组(10.71%)不良反应发生率比较,差异无统计学意义(P>0.05).结论 百合地黄汤加味联合艾司西酞普兰治疗能够有效改善围绝经期T2DM合并DD患者的血糖水平和血清性激素水平,降低患者抑郁症状评分和总分,提高临床疗效,且不增加不良反应发生率.
Objective To investigate the clinical efficacy of modified Baihe Dihuang decoction combined with escitalopram in the treatment of perimenopausal type 2 diabetes mellitus(T2DM)with depressive disor-der(DD)and its effect on blood glucose and depressive symptoms.Methods A total of 112 perimenopausal patients with T2DM and DD admitted to the hospital from August 2022 to March 2024 were selected as the re-search objects,and they were divided into lily group and escitalopram group by random number table method,with 56 cases in each group.Both groups were treated with conventional treatment,the escitalopram group was treated with escitalopram,and the lily group was treated with Baihe Dihuang decoction+escitalopram.The levels of blood glucose indexes[fasting plasma glucose(FPG),average postprandial 2 h plasma glucose(2 hPG),glycosylated hemoglobin(HbA1c)],depressive symptom score and total score,serum sex hormones[follicle stimulating hormone(FSH),estradiol(E2),luteinizing hormone(LH)],clinical efficacy,and adverse reactions were compared between the two groups.Results After treatment,the levels of FPG,2 hPG,HbA1c,E2,FSH and LH in the two groups were lower than those before treatment,and the level of E2 was higher than that before treatment,and the levels of FPG,2 hPG,HbA1c,FSH and LH in the lily group were lower than those in the escitalopram group,and the level of E2 was higher than that in the escitalopram group,and the differences were statistically significant(P<0.05).After treatment,the scores of depression,guilt,suicide,insomnia in the first stage of difficulty falling asleep,insomnia in the middle stage of not deep sleep,insomnia in the end of early waking,work and interest,block,agitation,mental anxiety,somatic anxiety,gas-trointestinal symptoms,sexual symptoms,suspicious pain,weight loss,insight in Hamilton depression scale and Hamilton depression scale total score in the two groups were lower than those before treatment,and the above symptom socres and total scores in the lily group were lower than those in the escitalopram group,and the differences were statistically significant(P<0.05).The total effective rate of lily group was 94.64%,which was higher than 71.43%of escitalopram group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the lily group(5.36%)and the escitalopram group(10.71%,P>0.05).Conclusion Modified Baihe Dihuang decoction combined with escitalopram can effectively improve the blood glucose level and serum sex hormone level of perimenopausal T2DM patients with DD,reduce the depressive symptom score and total score,improve the clinical efficacy,and do not increase the incidence of adverse reactions.
许冬舒;张宏信;宗耀华
河北省邢台市中医医院糖尿病院区内十科,河北 邢台 054000河北省邢台市中医医院糖尿病院区内十科,河北 邢台 054000河北省邢台市中医医院糖尿病院区内十科,河北 邢台 054000
医药卫生
围绝经期2型糖尿病抑郁症艾司西酞普兰百合地黄汤加味临床疗效
perimenopausetype 2 diabetes mellitusdepressive disorderescitaloprammodified Baihe Dihuang decoctionclinical efficacy
《检验医学与临床》 2026 (5)
596-601,608,7
河北省科技成果转化社会公益类(医疗卫生)项目(913-00-2018-233).
评论